July 21, 2026
Ophthalmic pharmaceutical company Orasis Pharmaceuticals announced two new offerings that provide eyecare professionals (ECPs) more ways to help patients start and stay on Qlosi® (pilocarpine hydrochloride ophthalmic solution) 0.4%.
The First Fill Free, offered through pharmacy partner BlinkRx, provides patients with a no-cost first-fill on their eyecare professional’s prescription, with standard pricing thereafter.
Qlosi is also now available for in-office dispensing in states where permitted. Together with home delivery through BlinkRx, these options ECPs and their patients more ways to access Qlosi, reinforcing Orasis’ optometry-focused approach to presbyopia care.
RISING REFILL RATES
Since launching in the U.S. in April 2025, thousands of ECPs are prescribing, and refill rates have reached 48%1, approximately double the rates typically observed with dry eye prescription therapies at retail pharmacies2, signaling patients are seeing meaningful near-vision improvement and staying on treatment, the company says. No retinal tears or retinal detachments have been reported to the FDA3, and real-world experience remains consistent with the efficacy, tolerability, and safety seen in Qlosi’s pivotal Phase 3 trials4.
“Our goal has always been to help patients see clearly up close without reaching for readers,” said Elad Kedar, chief executive officer of Orasis Pharmaceuticals. “We built Qlosi around eyecare professionals, not a direct-to-patient telehealth pathway. First Fill Free through BlinkRx and in-office dispensing give ECPs and patients more ways to access Qlosi, and a 48% refill rate, roughly double what is typically seen with dry eye prescription therapies at retail, tells us patients are seeing a meaningful result and choosing to stay on treatment.”
CONNECTED TO THE PATIENT’S ECP
Each option keeps the prescribing relationship with the patient’s ECP. First Fill Free and home delivery reach patients through BlinkRx, while in-office dispensing lets patients leave the visit with treatment in hand in states where permitted.
“The efficacy, tolerability, and safety I see in practice match the clinical trials, and my patients are relieved to finally have an option beyond readers. A no-cost first fill through BlinkRx removes a barrier to starting, and having Qlosi in the office lets me start the right patient during the visit, which is what I prefer,” said David Rouse, OD, FAAO, Rouse Family Eye Care, SECO President, and Chair of the Florida Board of Optometry.
For more information about First Fill Free through BlinkRx and how to prescribe Qlosi, click here. To order Qlosi for in-office dispensing, click here. ECPs can also contact their Orasis Key Account Manager.
Qlosi U.S. Indication and Important Safety Information
Indication and Usage
Qlosi® (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic agonist indicated for the treatment of presbyopia in adults.
Important Safety Information
CONTRAINDICATIONS
- Hypersensitivity
WARNINGS AND PRECAUTIONS
- Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.
- Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters or vision loss.
- Qlosi is not recommended to be used when iritis is present.
- Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the installation of Qlosi and wait 10 minutes before reinsertion.
- Avoid touching the tip of the vial to the eye or any other surface.
ADVERSE REACTIONS
- The most common adverse reactions (5% to 8%) are instillation site pain and headaches.
Please see full Prescribing Information here.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
References
- Data on file.
- Young, Kate. Patients with DED prescribed Miebo have higher refills rates than those on cyclosporine. Primary Care Optometry News. June 24, 2024. https://www.healio.com/news/optometry/20240624/patients-with-ded-prescribed-miebo-have-higher-refill-rates-than-those-on-cyclosporine
- FDA Adverse Events Monitoring System (AEMS) Public Dashboard for Drugs and Biologics. Accessed July 9, 2026. https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/33a0f68e-845c-48e2-bc81-8141c6aaf772/state/analysis
- Holland E, Karpecki P., Fingeret M., et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005.
Visit Orasis Pharmaceuticals here.
Learn more about BlinkRx here.
